Transaction DateRecipientSharesTypePriceValue
8th February 2021Advisors Llc Perceptive1,250,000Open or private purchase$16.00$20,000,000.00
8th February 2021Advisors Llc Perceptive1,770,600Conversion of derivative$0.00
8th February 2021Advisors Llc Perceptive2,941,769Conversion of derivative$0.00
8th February 2021Advisors Llc Perceptive2,857,795Conversion of derivative$0.00
28th January 2021Advisors Llc Perceptive4,219,409Open or private purchase$2.37$9,999,999.33
25th January 2021Advisors Llc Perceptive311,111Open or private purchase$22.50$6,999,997.50
22nd January 2021Advisors Llc Perceptive285,151Open or private sale$8.16$2,326,832.16
22nd January 2021Advisors Llc Perceptive550,000Open or private sale$1.48$814,000.00
22nd January 2021Advisors Llc Perceptive33,849Open or private sale$8.95$302,948.55
21st January 2021Advisors Llc Perceptive674,352Open or private sale$1.68$1,132,911.36
Aldeyra Therapeutics
Aldeyra Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Aldeyra Therapeutics, Inc. is a biotechnology company. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases.

Ticker: ALDX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1341235
Employees: 20
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Common Stock, Shares, Issued: $33 M (15%)